Inflectra (Intravenous)
Generic name:infliximab-dyyb (intravenous route) [ in-FLIX-i-mab-- dyyb ]
Drug class:TNF alfa inhibitors
Medically reviewed by Drugs.com. Last updated on Apr 14, 2022.
Increased risk of serious infections leading to hospitalization or death, including TB, bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. Discontinue infliximab-dyyb if a patient develops a serious infection. Perform test for latent TB; if positive, start treatment for TB prior to starting infliximab-dyyb. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab. Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including infliximab products. Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. The majority of reported cases have occurred in patients with Crohn’s disease or ulcerative colitis, most of whom were adolescent or young adult males .
Commonly used brand name(s)
In the U.S.
- Inflectra
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Immunological Agent
Pharmacologic Class: Infliximab
Uses for Inflectra
Infliximab-dyyb injection is used in adults to treat Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis. It is also used in children to treat Crohn disease and moderate to severely active ulcerative colitis. Infliximab-dyyb is a monoclonal antibody that works to enhance and improve the immune system.
This medicine is to be given only by or under the direct supervision of your doctor.
Before using Inflectra
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of infliximab-dyyb injection for the treatment of Crohn disease or ulcerative colitis in children 6 years of age and older. However, safety and efficacy have not been established in children younger than 6 years of age.
Appropriate studies performed to date have demonstrated that infliximab-dyyb injection is not helpful in children with juvenile rheumatoid arthritis. Efficacy has not been established.
Geriatric
Ap..
